Drug intelligence / Profile preview

R333

Development stage: Discontinued
Lead developer: Rigel Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

R333 is a topical small molecule drug developed by Rigel Pharmaceuticals as a dual Janus kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor. It was investigated for the treatment of discoid lupus erythematosus (DLE), a chronic autoimmune skin condition. The drug acts by inhibiting both JAK and SYK signaling pathways, which are involved in inflammatory and immune responses. R333 advanced to Phase 2 clinical trials but did not meet its primary endpoint in efficacy for DLE, leading Rigel to discontinue further development for this indication.

Other names: R333 6% ointment

Targets

SYK (Spleen Tyrosine Kinase)JAK (Janus kinase family)

Beyond the preview

Go deeper on R333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R333.

Explore the full profile